Indaptus Therapeutics INDP Stock Is It a Good Entry Point Indaptus Therapeutics misses EPS views no revenue Wells Fargo Company WFC Recent Analyst Rating Divergence Price Performance and Jim Cramers Historical Position Disclosure FBIOP Fortress reports wider than expected Q4 2025 loss even as shares gain 626 percent today